Embed
Email

Disclosure

Document Sample

Shared by: qinmei liao
Categories
Tags
Stats
views:
0
posted:
12/15/2011
language:
pages:
12
Disclosure

Speaker name: Prof. Ulrich Hoffmann

University Hospital Munich





I have the following potential conflicts of interest to

report:

Consulting

Employment in industry

Stockholder of a healthcare company

Owner of a healthcare company

Other(s)

X I do not have any potential conflict of interest





University Hospital LMU München

SFA lesions should primarily be treated conservatively









Ulrich Hoffmann



Dept. of Angiology

University Hospital Munich, Germany









University Hospital LMU München

Outcome of intermittent claudication





100 pts. presenting to doctor with IC









5 y limb outcome 5 y systemic

outcome







75 stabilise 25 5 to 10 30 will die 55 to 60 will be alive

or improve will deteriorate non-fatal CV without CV events

events







5 interventions 16 cardiac

2 major amputations 4 cerebral

3 other vascular

7 non-vascular

TASC, Int Angiol 2000, 19, Suppl. 1

University Hospital LMU München

Treatment for IC....



• Should not expose the patient to

additional risks for deteorating

claudication or for limb loss

• Should not expose the patient to

additional risk for CV events and

mortality

• Should be effective and durable





University Hospital LMU München

Pooled results of femoropopliteal catheter

interventions



1-y patency 3-y patency 5-y patency

(%) (%) (%)



PTA 77 (78 – 80) 61 (55-68) 55 (52-62)

(stenosis)



PTA 65 (55 – 71) 48 (40 – 55) 42 (33 – 51)

(occlusion)



PTA/Stent 75 (73 – 79) 66 (64 – 70) -

(stenosis)



PTA/Stent 73 (69 – 75) 64 (59 – 67) -

(occlusion)



Predictors of restenosis: length of lesion, femoral vs popliteal, outflow disease

Complication rate: 1-12 %



Muradin et al. Radiology 2001;221:137

TASC II Eur J Vasc Endovasc Surg 2007;33 Supl.1

TASC I, Int Angiol 2000, 19, Suppl. 1

University Hospital LMU München

Outcome following femoropopliteal bypass



5 y patency (%)



Vein 74 – 76 %



PTFE 39 – 52 %



TASC II Eur J Vasc Endovasc Surg 2007;33 Supl.1









Early complication rate: 5 - 10 % (TASC I, Int Angiol 2000, 19, Suppl. 1)

30-day mortality rate: 0,7 – 4,4 % (NHS Economic Evaluation Database, 2002

deVries Radiology 2000;222:25)









Failed femoropoliteal grafts for IC carry a substantial risk of

limb loss, especially when vein is not used (19/55 failed PTFE

grafts) (Renwick Br J Surg 1999;86:639)







University Hospital LMU München

Exercise training in intermittent claudication







• improves pain free walking

time by an avarage of 180

%, improves QoL

• has no associated

mortality and morbidity

• improves blood pressure,

blood lipids and glycemic

control

• potentially reduces CV risk







Gardner AW, Poehlman ET. JAMA 1995;274:975-80.

Hall JA, Barnard J. J Cardiac Rehabil 1982;2:569-74.

Rosfors S, Bygdeman S, Arnetz BB, et al. Scand J Rehabil Med 1989;21:7-11.







University Hospital LMU München

Cilostazol for IC





• Improvement in Walking Distance measured in 9 Efficacy Trials with

reproducible Statistical Significance and Clincally meaningful Effect

nd

(for 6 of the 9 Trials) pto ms a

e sym

improv AD a

nd

to yP

• In 1 Efficacy Trial: e rapy extremit

5): ective th lower

99% in Pain-free 00 eff Claudication Distance ( p=0,0001)

(2 (Initial) ith

i de line s an nts w

a tie

86% GuMaximum (Absolute) Claudication Distance (p=0,0001)

C in dicated

/ AC ce in pa

AHA azol is in g distan .

• Cilost e walkinIn iQuality of Life (SF-36) measured in 5 of the Efficacy

Improvement tion

as u d ca

Trials ttent cla

incre i

rm lA

Leve

inteBodily Pain:

, 4x better (p=0,0001)

Cl a ss 1

Physical Function: 4x better (p=0,0001)

Role Physical: 6x better (p=0,0004)









University Hospital LMU München

The patient with IC should be informed

about...







• the minimal risk for amputation

• the limited durability and associated

risks of revascularization

• effective conservative measures

• their high risk for CV events







University Hospital LMU München

Treatment strategy for IC









TASC II Eur J Vasc Endovasc Surg 2007;33 Supl.1



University Hospital LMU München

Thank you for your attention !



Related docs
Other docs by qinmei liao
OVG lash curler
Views: 0  |  Downloads: 0
Mass Spectrometry of Proteins and Peptides
Views: 23  |  Downloads: 0
as at Lienrtcwi
Views: 0  |  Downloads: 0
ESTIMATION OF POPULATION PARAMETERS
Views: 0  |  Downloads: 0
THE LARGE MASK TECHNICAL DESCRIPTION
Views: 0  |  Downloads: 0
Photosynthesis Cell Respiration
Views: 0  |  Downloads: 0
Masters Program in Financial Management
Views: 0  |  Downloads: 0
Ambulance Services EDITOR NOTE Original
Views: 0  |  Downloads: 0
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!